Teligent (NASDAQ:TLGT) is scheduled to announce its Q4 earnings results before the market opens on Monday, March 18th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.
Shares of Teligent stock opened at $1.40 on Friday. Teligent has a 52-week low of $1.13 and a 52-week high of $4.52. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 3.30. The stock has a market cap of $78.51 million, a PE ratio of -7.37 and a beta of 1.59.
A number of research analysts have recently issued reports on TLGT shares. Canaccord Genuity dropped their price target on shares of Teligent from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Friday, November 16th. ValuEngine upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.
A hedge fund recently raised its stake in Teligent stock. Geode Capital Management LLC increased its stake in shares of Teligent Inc (NASDAQ:TLGT) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 479,485 shares of the company’s stock after buying an additional 17,951 shares during the period. Geode Capital Management LLC owned about 0.89% of Teligent worth $656,000 as of its most recent filing with the Securities and Exchange Commission. 64.73% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by Zolmax and is the property of of Zolmax. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://zolmax.com/investing/teligent-tlgt-set-to-announce-quarterly-earnings-on-monday/2966273.html.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.